|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF inhibitors are also efficacious for other inflammatory joint and spine diseases, and have been approved for inflammatory bowel disease, uveitis and psoriasis.
|
31639514 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Investigations into the genetics of psoriasis has spurred further examinations into the contributions of immune mediators such as IL-23, IL-17, IL-22, and TNF as well as cellular mediators including a variety of dendritic cell populations of the skin and the growing number of T cell types, including the Th17 and Th22 subsets.
|
21317854 |
2011 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results strongly suggest that increased activation of MK2 is responsible for the elevated and posttranscriptionally regulated TNF-alpha protein expression in psoriatic skin, making MK2 a potential target in the treatment of psoriasis.
|
16424170 |
2006 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-17A inhibitors are a promising alternative to tumor necrosis factor-α inhibitors for the treatment of psoriasis.
|
31017250 |
2019 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.
|
27044681 |
2017 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-24 was strongly expressed in human psoriatic epidermis, and pharmacological inhibition of NF-κB increased IL-24 expression in TNF-stimulated human primary keratinocytes, suggesting that this mechanism is relevant for human psoriasis.
|
24211183 |
2013 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
|
28211161 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
High levels of the pro-inflammatory cytokine tumour necrosis factor (TNF) have been associated with many diseases including rheumatoid arthritis (RA), ankylosing spondylitis (AS), inflammatory bowel disease (IBD) and psoriasis.
|
26321488 |
2016 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analyzed three SNPs in IL-17A (rs2275913 and rs10484879) and IL-17F (rs763780) to look for an association with psoriasis and/or with response to anti-TNF drugs or ustekinumab.
|
26415694 |
2015 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, IL-17A and TNF-α in PSO patients were negatively associated with the Gαq expression.
|
30654308 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF is critically involved in the pathogenesis of psoriasis.
|
21672030 |
2011 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients underwent TNF-α therapy for an average of 14.0 months before psoriasis onset with 69.9% of patients experiencing onset within the first year.
|
27720274 |
2017 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, expression of TNF-α tended to be higher in psoriasis patients.
|
29428424 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of TNF-α inhibitors in patients with psoriasis and metabolic syndrome: a preliminary study.
|
28421729 |
2020 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis suggests that TNF-α 308 G/A polymorphism is associated with decreased risk of psoriasis, while TNF-α 238 G/A is associated with increased risk of psoriasis.
|
24324571 |
2013 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasis is an immune-mediated disease where the IL-23/Th17 axis as well as TNF comprise main targets of biological therapy.
|
30307657 |
2018 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These skin-infiltrating lymphocytes might trigger, by the local production of Th-1 cytokines such as TNF-alpha and interferon-gamma (IFN-gamma), the eruption of psoriatic plaques in patients with a genetic predisposition for psoriasis.
|
16441627 |
2006 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor-alpha (TNF-α) immunotherapy has revolutionized the treatment of inflammatory diseases, such as psoriasis and psoriatic arthritis.
|
31719235 |
2020 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Corticosteroids, cyclosporine, tumor necrosis factor alpha (TNF-α) inhibitors and, more recently, interleukin (IL)-17A inhibitors have revolutionized the treatment of psoriasis, each in its own way and time.
|
28770513 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
While the previously reported association between TNF*-238A and psoriasis seems to primarily reflect LD with PSORS1, TNF*-857T may represent a risk factor for PsA that is independent of the PSORS1 allele.
|
17530646 |
2007 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis.
|
18209089 |
2008 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paradoxical psoriasis manifestations in inflammatory bowel disease (IBD) under tumour necrosis factor (TNF)-inhibitor therapy have been reported and paradoxical IBD occurred rarely (mostly Crohn disease) in patients with rheumatological conditions treated with infliximab or etanercept.
|
28477389 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
It was proposed that TNF-alpha is involved in the pathogenesis of psoriasis, and it is therefore suggested that TACE has important roles in psoriasis.
|
15888146 |
2005 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, TRAIL-neutralization in an imiquimod-induced murine psoriasis model remarkably improved skin phenotypes, such as ear thickness, and TNF-α expression in lesional skin.
|
29661487 |
2018 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.
|
31672774 |
2020 |